Rafael Holdings is a clinical stage biotechnology company focused on helping patients
with difficult to treat diseases. Our recent merger with Cyclo Therapeutics, brings
together two innovative companies with a mission to deliver a breakthrough treatment
option for patients with Niemann Pick Type C1.

Rafael Holdings invests in novel cancer therapeutics that have the potential to improve and extend the lives of patients.

Press Releases

Press Release